Delaugerre C - Search Results

1

[Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T].

Mouroux M, Izopet J, Descamps D, Delaugerre C, Yvon-Groussin A, Angleraud F, Coutellier A, Bonmarchand M, Valantin MA, Matheron S, Agut H, Katlama C, Brun-Vezinet F, Calvez V. Mouroux M, et al. Among authors: delaugerre c. Pathol Biol (Paris). 2000 Jun;48(5):508-12. Pathol Biol (Paris). 2000. PMID: 10949850 French.

2

[Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].

Mouroux M, Bossi P, Yvon-Groussin A, Delaugerre C, Valantin MA, Tubiana R, Coutellier A, Bonmarchand M, Bricaire F, Katlama C, Agut H, Huraux JM, Calvez V. Mouroux M, et al. Among authors: delaugerre c. Pathol Biol (Paris). 1999 May;47(5):549-52. Pathol Biol (Paris). 1999. PMID: 10418038 French.

3

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F. Descamps D, et al. Among authors: delaugerre c. JAMA. 2000 Jan 12;283(2):205-11. doi: 10.1001/jama.283.2.205. JAMA. 2000. PMID: 10634336 Clinical Trial.

4

Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance.

Mouroux M, Yvon-Groussin A, Peytavin G, Delaugerre C, Legrand M, Bossi P, Do B, Trylesinski A, Diquet B, Dohin E, Delfraissy JF, Katlama C, Calvez V. Mouroux M, et al. Among authors: delaugerre c. J Clin Microbiol. 2000 Jul;38(7):2726-30. doi: 10.1128/JCM.38.7.2726-2730.2000. J Clin Microbiol. 2000. PMID: 10878071 Free PMC article. Clinical Trial.

5

Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.

Carcelain G, Tubiana R, Samri A, Calvez V, Delaugerre C, Agut H, Katlama C, Autran B. Carcelain G, et al. Among authors: delaugerre c. J Virol. 2001 Jan;75(1):234-41. doi: 10.1128/JVI.75.1.234-241.2001. J Virol. 2001. PMID: 11119593 Free PMC article.

6

CD4+Ki67+ lymphocytes in HIV-infected patients are effector T cells accumulated in the G1 phase of the cell cycle.

Combadère B, Blanc C, Li T, Carcelain G, Delaugerre C, Calvez V, Tubiana R, Debré P, Katlama C, Autran B. Combadère B, et al. Among authors: delaugerre c. Eur J Immunol. 2000 Dec;30(12):3598-603. doi: 10.1002/1521-4141(200012)30:12<3598::AID-IMMU3598>3.0.CO;2-E. Eur J Immunol. 2000. PMID: 11169402 Free article.

7

Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice.

Delaugerre C, Mouroux M, Yvon-Groussin A, Simon A, Angleraud F, Huraux JM, Agut H, Katlama C, Calvez V. Delaugerre C, et al. Antimicrob Agents Chemother. 2001 Mar;45(3):946-8. doi: 10.1128/AAC.45.3.946-948.2001. Antimicrob Agents Chemother. 2001. PMID: 11181387 Free PMC article.

8

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.

Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V. Delaugerre C, et al. J Med Virol. 2001 Nov;65(3):445-8. J Med Virol. 2001. PMID: 11596076

9

Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure.

Delaugerre C, Valantin MA, Mouroux M, Bonmarchand M, Carcelain G, Duvivier C, Tubiana R, Simon A, Bricaire F, Agut H, Autran B, Katlama C, Calvez V. Delaugerre C, et al. AIDS. 2001 Nov 9;15(16):2189-91. doi: 10.1097/00002030-200111090-00016. AIDS. 2001. PMID: 11684940 Clinical Trial.

10

Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.

Mouroux M, Descamps D, Izopet J, Yvon A, Delaugerre C, Matheron S, Coutellier A, Valantin MA, Bonmarchand M, Agut H, Massip P, Costagliola D, Katlama C, Brun-Vezinet F, Calvez V. Mouroux M, et al. Among authors: delaugerre c. Antivir Ther. 2001 Sep;6(3):179-83. Antivir Ther. 2001. PMID: 11808752

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

300 results

Search Page

Filters